These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results Terminated 2004-004403-37 Eine monozentrische, randomisierte, kontrollierte Studie zur Untersuchung von Interferon-beta zur Behandlung der Multiplen-Sklerose (MS)-assoziierten und primären Uveitis intermedia im Vergleich zur S... 2011-03-31 due-trials
Reported results Terminated 2005-001762-13 Energy metabolism of critically ill children treated with lipid emulsion and carnitine 2005-07-07 due-trials
Reported results 2005-003201-81 GACHE: German trial of Acyclovir and Corticosteroids in Herpes-simplex-virus-Encephalitis. A multicenter, multinational, randomized, double-blind, placebo-controlled German, Austrian and Dutch trial. 2012-12-31 due-trials
Ongoing 2005-003911-63 Combined Radiochemotherapy with Erbitux (Cetuximab) plus Temozolomide in the primary therapy of Glioblastoma Multiforme (GBM) - Phase I/II Trial not-yet-due
Reported results Terminated 2006-001146-13 "Investigation of Caspofungin Plasma Concentration and Pharmacokinetic for the Improvement of the Antifungal Therapy in Patients of Surgical Intensive Care Unit" 2006-08-14 due-trials
Reported results 2006-001212-72 Therapie des nodalen Follikulären Non-Hodgkin-Lymphoms (WHO Grad I/II) im klinischen Stadium I / II mittels involved-field Bestrahlung in Kombination mit Rituximab (Mabthera Involved-field Radiotherap... 2014-04-10 due-trials
Reported results Terminated 2006-001732-53 Eine multizentrische, randomisierte, kontrollierte Studie zur Untersuchung von Adalimumab bei der Behandlung verschiedener Formen von refraktärer Uveitis im Vergleich zur Standardtherapie 2012-08-16 due-trials
Reported results 2006-002056-14 Akute Cholezystitis – Frühe laparoskopische Operation versus antibiotischer Therapie mit elektiver Cholezystektomie im Intervall (ACDC-Studie) (Acute cholecystitis – early laparoscopic surgery versus ... 2010-11-28 due-trials
Reported results 2006-002338-39 Pharmakokinetik von Linezolid bei Dialyse (pharmacokinetics of linezolid under dialysis) 2008-04-13 due-trials
Reported results 2006-005308-15 Pilot study of the safety and tolerance of preoperative melatonin application in patients undergoing major liver resection. 2009-03-30 due-trials
Reported results Terminated 2006-006573-24 Prospective influence of bedtime insulin glargine on mobilization and function of endothelial progenitor cells in patients with type 2 diabetes: a partially double-blind, randomized, three-arm unicent... 2009-06-17 due-trials
Reported results 2007-002755-16 Pharmakokinetik von Posaconazol verabreicht über Magensonde - POLICE-Studie (POsaconazoLe via gastrIC tubE) 2009-08-07 due-trials
Reported results Terminated 2007-004535-33 Phase II study on curative resectability of not optimally resectable liver and/or lung metastases from colorectal carcinoma (CRC) under intensified chemotherapy (FLOFOXIRI/Bevacizumab). 2011-03-16 due-trials
Exempt, with results 2007-005537-11 Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma or leukemia 2017-03-24 not-yet-due
Not reported 2008-001090-15 Randomized, double-blind Phase II study of Docetaxel + Sorafenib (Nexavar®) versus Docetaxel + Placebo in First-Line treatment of patients with HER2-negative, metastatic breast cancer. 2013-12-31 due-trials
Ongoing, reported early 2008-001669-27 A phase-III study on the value of allogeneic stem cell transplantation in poor-risk chronic lymphocytic leukemia by the German CLL Study Group (GCLLSG) and the German Cooperative Transplant Study Grou... not-yet-due
Reported results Terminated 2008-002667-13 A single-center controlled pilot study to investigate pre- and perioperative therapy with Sorafenib (Nexavar®) in patients who are candidates for a curative surgery of renal cell cancer (PREST = preop... 2013-09-10 due-trials
Not reported 2008-003174-18 Open-labeled, randomized multi-center phase II study evaluating the efficacy and safety of Paclitaxel/ Carboplatin with and without Cetuximab as first-line treatment of adeno- and undifferentiated car... 2020-01-31 due-trials
Reported results Terminated 2008-004696-22 An Open Label Randomized Multicentre Phase IIIb Trial Comparing Parenteral Substitution versus Best Supportive Nutritional Care in Subjects with Pancreatic Adenocarcinoma Receiving 5-FU plus Oxaliplat... 2014-08-21 due-trials
Listed as ongoing, but also has a completion date and reported results 2008-005653-37 Multicenter, prospective randomized trial on the use of prothrombin complex and fresh frozen plasma in patients with intracerebral hemorrhage related to vitamin K antagonists (VKA) 2015-02-06 bad-data
Reported results 2008-006871-60 Dose-intensified Rechallenge with Temozolomide, One Week on One Week Off versus Three Weeks on One Week Off in Patients with Progressive or Recurrent Glioblastoma 2013-06-30 due-trials
Not reported 2008-008513-19 Phase II Studie zur Wirksamkeit und Verträglichkeit von Vorinostat bei Patienten mit fortgeschrittenen, metastasierten Weichteilsarkomen. English title: A Phase II Study to Investigate the Efficacy an... 2013-09-13 due-trials
Reported results Terminated 2009-009277-10 Neoadjuvant Radiochemotherapy Combined with Panitumumab in Locally Advanced KRAS wild-type Rectal Cancer 2012-08-16 due-trials
Reported results 2009-009894-88 Lapatinib versus Lapatinib with Capecitabine as Second-line Treatment in Her2-Overexpressing Metastatic Gastro-Esophageal Cancer: A randomized phase II trial 2013-04-24 due-trials
Not reported 2009-013279-23 In vivo response monitoring of treatment with the EGFR-monoclonal-antibody Cetuximab in metastatic colorectal cancer – a single center phase II study 2016-12-21 due-trials
Not reported 2009-013856-61 A phase III national, multicentre, randomized open-label study with Lenalidomide/Dexamethasone versus Lenalidomide/Dexamethasone and autologous stem cell transplantation followed by Lenalidomide 2017-06-30 due-trials
Completed, but no date 2009-016631-35 Phase II Trial of Ipilimumab in Patients with advanced melanoma and spontaneous preexisting immune response to NY-ESO-1 bad-data
Exempt, with results Terminated 2009-017328-25 A phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer 2015-10-15 not-yet-due
Not reported 2010-019173-16 Randomised phase III trial for previously untreated multiple myeloma to evaluate two regimens of bortezomib based induction therapy and lenalidomide consolidation followed by lenalidomide maintenance ... 2017-03-11 due-trials
Exempt, with results Terminated 2010-022425-15 ACCEPT - (ACC, Erbitux® and particle therapy) - Combined treatment of adenoid cystic carcinoma with cetuximab and IMRT plus C12 heavy ion boost (Phase I/II feasibility study) not-yet-due
Exempt 2011-000921-61 A phase I/II, randomized, open-label, multi-centre study of BIBF1120 + reirradiation (R-RT) versus reirradiation in the treatment of patients with first or second progression of glioblastoma 2017-09-30 not-yet-due
Not reported 2011-001491-20 A phase II trial to evaluate the safety, feasibility and efficacy of a salvage therapy consisting of the mTOR inhibitor Temsirolimus (Torisel™) added to the standard therapy of Rituximab and DHAP for ... 2018-11-01 due-trials
Not reported 2011-003273-28 Treatment of patients with metastatic melanoma (AJCC stage IV or III unresectable) with the PDE-inhibitor Tadalafil: A Pilot Trial for “Proof of Principle” 2015-03-25 due-trials
Not reported 2012-001650-26 A randomised, placebo-controlled, double-blind, monocentre study on the application of physostigminsalicylate (Anticholium®) as adjunctive measure in perioperative sepsis/septic shock 2017-02-18 due-trials
Reported results Terminated 2012-003528-19 STEM CELL TRANSPLANTATION FOR ERADICATION OF MINIMAL 2016-06-13 due-trials
Listed as ongoing, but also has a completion date and reported results 2012-003609-80 European Cooperative Acute Stroke Study-4: Extending the time for thrombolysis in emergency neurological deficits. 2017-12-18 bad-data
Reported results Terminated 2013-000211-24 A multicenter, randomized, placebo-controlled, double-blind proof of concept study to evaluate the efficacy and safety of the human normal immunoglobulin Intratect® 5% for intravenous use as adjuvant ... 2014-12-10 due-trials
Not reported 2013-005485-19 Bendamustine, Prednisone and Velcade® for first-line treatment of patients with symptomatic multiple myeloma not eligible for high-dose chemotherapy followed by autologous stem cell transplantation (B... 2019-08-01 due-trials
Ongoing 2014-001991-76 Initial treatment of idiopathic nephrotic syndrome in children with mycophenolate mofetil vs. prednisone: A randomized, controlled, multicenter study not-yet-due
Ongoing 2014-003079-40 A randomized phase III trial on the effect of elotuzumab in VRD induction /consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma not-yet-due
Exempt 2015-002752-27 Umbrella protocol for phase I/IIa trials of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter methylation: NCT Neuro Master M... not-yet-due
Ongoing 2015-003920-30 Phase-II study on the value of post-transplant Cyclophosphamide after Thiotepa-based haplo-identical stem-cell transplantation for relapsed-refractory lymphoma not-yet-due
Ongoing 2016-002059-89 Therapy of Nodal Follicular Non-Hodgkin Lymphoma (WHO grade 1/2) in Clinical Stage I/II using Response Adapted Involved Site Radiotherapy in Combination with Gazyvaro not-yet-due
Ongoing 2016-004660-19 CDK4/6 inhibition in locally advanced/metastatic chordoma not-yet-due
No trial status on register 2016-004786-80 A phase IIa, randomized, placebo-controlled, double-blind, cross-over study to evaluate safety and efficacy of subcutanous administration of anakinra in patients with cystic fibrosis. bad-data
Exempt 2016-004808-60 Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector - A unicenter Phase I /II clinical trial not-yet-due
Ongoing 2017-001755-31 Randomized Phase-II Study of Trabectedin/Olaparib Compared to Physician’s Choice in Subjects with Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies not-yet-due
Ongoing 2017-004768-37 A randomized phase III trial assessing the benefit of the addition of isatuximab to lenalidomide / bortezomib / dexamethasone (RVd) induction and lenalidomide maintenance in patients with newly diagno... not-yet-due
Ongoing 2017-005158-12 TEAM-Trial: Targeting Epigenetic therapy resistance in AML with Bortezomib: A multi-centre matched threshold crossing phase II approach not-yet-due
Completed, reported early Terminated 2018-000112-21 Prospective Window of opportunity trial 3 weeks neoadjuvant Anastrozole in Postmenopausal Women with Estrogen receptor positive (ER+) Breast Cancer 2020-03-13 not-yet-due
Exempt 2018-000127-14 INFORM2 exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies not-yet-due
Completed, but no date Terminated 2018-002606-31 Sublingual versus intravenous Fentanyl in patients with acute trauma - a randomized, double-blind, double-dummy study to demonstrate non-inferiority bad-data
Ongoing 2018-002675-17 Quizartinib and High-dose Ara-C plus Mitoxantrone in Relapsed/Refractory AML with FLT3-ITD not-yet-due
Exempt 2018-002979-17 Use of doxapram as a new antiarrhythmic drug for a specific therapy of atrial fibrillation not-yet-due
Ongoing 2018-004562-33 A phase II, open-label, non-randomized, multi-center study evaluating the efficacy and safety of nivolumab plus ipilimumab in patients with cancer of unknown primary site who are relapsed after or ref... not-yet-due
Ongoing 2018-005027-16 Improvement of functional Outcome for patients with newly diagnosed grade II or III glioma with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 trial not-yet-due
Exempt 2019-001759-38 Pharmacokinetics of a microdosed cocktail containing rivaroxaban, apixaban and edoxaban in children with congenital heart defects not-yet-due
Ongoing 2019-002461-35 Monocenter, randomized, controlled, open-label, phase-II clinical trial of PREoperative endoscopic injection of BOTulinum toxin in the sphincter of Oddi to reduce postoperative pancreatic fistula afte... not-yet-due
Ongoing 2019-003913-32 Randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare intensive postremission therapy double blinded with or without gla... not-yet-due
Ongoing 2020-001632-10 A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Dise... not-yet-due